Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Sponsor: Massachusetts General Hospital
Summary
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
Official title: PROACT 3: Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Key Details
Gender
All
Age Range
30 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2025-10-15
Completion Date
2027-08-15
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
Immediate disclosure of CAD PRS results
Participants receive their CAD PRS results as soon as they are available after genotyping.
Deferred Disclosure of CAD PRS results
Participants receive their CAD PRS results after completion of the 12 month follow up period.
Locations (1)
Massachusetts General Hospital
Boston, Massachusetts, United States